Clinical Commander

Back to dossier
cardio.nstemi.dialysis-troponin-interpretation.v1PRODUCTION
cardio.nstemi.dialysis-troponin-interpretation.v1

NSTEMI in dialysis/ESKD — troponin delta (not absolute) drives diagnosis; renally-reconciled therapy

cardiologyacuteadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

NSTEMI in ESKD: troponin is chronically elevated at baseline (especially hs-cTnT); diagnosis depends on a DYNAMIC rise/fall plus ischaemic context (4th UDMI), not a single absolute value. Cardiovascular death is the leading mortality cause; dialysis patients are systematically under-revascularised

Inputs
1
Actions
0
Advance rule
Set
Advance when

delta-based diagnostic frame + ESKD context established

Patient inputs (10)

Anaemia of CKD is a major demand-ischaemia (type 2 MI) driver and a bleeding/transfusion consideration for an invasive strategy

ESKD patients have markedly elevated cardiovascular mortality across ages; informs invasive-strategy and bleeding-risk balance

Anchor symptom; atypical equivalents (dyspnoea, intradialytic hypotension, fatigue) are common from autonomic neuropathy

Ischaemia assessment, confounded by LVH/strain and electrolyte shifts; serial ECGs around dialysis add value

Haemodialysis vs peritoneal, last/next session timing, residual renal function and anuria status drive peri-dialytic risk, anticoagulant choice and contrast considerations

hs-cTnT is more elevated at baseline in ESKD than hs-cTnI; a documented prior baseline transforms an absolute value into an interpretable delta

Serial measurement (0/1-2-3 h per assay) to establish a rise/fall pattern — the diagnostic cornerstone in chronically elevated baselines

Potassium/calcium shifts peri-dialysis affect ECG and arrhythmic/ischaemic risk and antiarrhythmic safety

AV fistula/graft preservation and elevated bleeding risk in uraemia shape antithrombotic dosing and radial-vs-femoral access planning

Sex modifies troponin URLs and presentation; relevant to assay-specific interpretation

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationalseveresignificant_dynamic_troponin_delta_with_ischaemic_context
    A clear rise and/or fall of troponin (e.g. ≥20% from an elevated baseline, or beyond assay biological variation) with ischaemic symptoms/ECG/imaging in an ESKD patient — type 1 NSTEMI, NOT "chronic ESKD elevation"
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremajor_bleeding_from_non_renally_reconciled_antithrombotics
    Major bleeding in an ESKD NSTEMI patient given fondaparinux or unreduced treatment-dose enoxaparin, or excessive DAPT, without renal reconciliation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatechronically_elevated_but_stable_troponin_misread_as_acute
    A stable, chronically elevated troponin (no significant serial change) in an ESKD patient being treated as acute MI — risks unnecessary anticoagulation/catheterisation and bleeding harm
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateintradialytic_hypotension_driven_type2_mi
    Troponin rise temporally linked to recurrent intradialytic hypotension, severe anaemia, or a high-output AV fistula — type 2 (demand) MI rather than plaque rupture
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateeskd_down_triaged_inappropriately_from_invasive_strategy
    A confirmed type 1 NSTEMI patient denied a timely invasive strategy on the basis of ESKD alone — a documented care-gap that worsens outcomes
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

ESKD NSTEMI antithrombotic + anti-ischaemic therapy — UFH preferred for ACS anticoagulation in dialysis; renally reconcile all agents; do not withhold an invasive strategy on ESKD alone (4th UDMI; 2023 ESC ACS; ISCHEMIA-CKD)
axis: eskd_nstemi_renally_reconciled_antithrombotics_ufh_preferred
Selected axis "ESKD NSTEMI antithrombotic + anti-ischaemic therapy — UFH preferred for ACS anticoagulation in dialysis; renally reconcile all agents; do not withhold an invasive strategy on ESKD alone (4th UDMI; 2023 ESC ACS; ISCHEMIA-CKD)" by default fallback (first axis)
  • aspirin
    first line
    antiplatelet_cox1
    162-325 mg load then 81 mg PO daily • PO • daily
    triggers: confirmed_type1_nstemi_in_eskd
    2023 ESC ACS — foundational antiplatelet; benefit maintained in CKD/ESKD though under-prescribed
    rxcui 1191
  • ticagrelor
    first line
    p2y12_inhibitor
    180 mg load then 90 mg PO BID • PO • BID
    triggers: type1_nstemi_invasive_strategy_planned
    2023 ESC ACS — not renally dose-adjusted; PLATO renal subgroup showed preserved benefit; balance against high ESKD bleeding risk
    rxcui 1116632
  • clopidogrel
    second line
    p2y12_inhibitor
    300-600 mg load then 75 mg PO daily • PO • daily
    triggers: ticagrelor_intolerance_or_high_bleeding_risk, eskd_nstemi_dapt
    No renal dose change; acceptable alternative when ticagrelor unsuitable; lower bleeding signal in very-high-risk ESKD
    rxcui 32968
  • heparin (unfractionated)
    first line
    unfractionated_heparin
    weight-based IV per ACS protocol, aPTT/anti-Xa titrated • IV • continuous, monitored
    triggers: eskd_nstemi_anticoagulation, dialysis_patient_acs
    2023 ESC ACS — UFH preferred in dialysis: titratable, not renally cleared, predictable peri-procedural management around dialysis
    rxcui 235473
  • enoxaparin (renally reduced)
    second line
    lmwh
    1 mg/kg SC ONCE daily (renal reduction) with anti-Xa monitoring if used • SC • daily
    triggers: ufh_unsuitable_and_lmwh_chosen_with_anti_xa_monitoring
    Renally cleared — accumulates in ESKD; if used at all, reduce to once-daily with anti-Xa monitoring; UFH generally preferred
    rxcui 67108
  • atorvastatin
    first line
    statin
    80 mg PO daily (high-intensity) • PO • daily
    triggers: acs_secondary_prevention_eskd
    High-intensity statin for ACS; note dialysis-initiation statin trials (4D/AURORA) were neutral for primary prevention but ACS secondary prevention still indicated
    rxcui 83367
  • metoprolol
    add on
    beta_blocker
    12.5-25 mg PO BID, cautious uptitration • PO • BID
    triggers: post_nstemi_eskd_no_contraindication
    Post-MI benefit; cautious dosing given intradialytic-hypotension and dialysability considerations (metoprolol partially dialysed)
    rxcui 6918
  • AVOID fondaparinux in severe renal failure
    contraindication substitute
    do_not_use
    AVOID if CrCl <20-30 / dialysis • N/A • N/A
    triggers: eskd_acs_anticoagulation_choice
    2023 ESC ACS / label — fondaparinux is renally cleared and contraindicated in severe renal impairment/dialysis (accumulation, bleeding)
  • AVOID reflexive enoxaparin treatment-dose without renal reduction
    contraindication substitute
    do_not_use
    AVOID standard BID treatment dosing in ESKD • N/A • N/A
    triggers: eskd_acs
    Accumulation → major bleeding; if LMWH used, reduce dose + anti-Xa monitor; UFH preferred
  • Coronary angiography ± PCI with radial access + dialysis timing
    rescue
    invasive_strategy
    Timely invasive strategy for confirmed type 1 NSTEMI; radial access; coordinate dialysis pre/post; protect residual renal function if not anuric • N/A • per risk stratification
    triggers: confirmed_type1_nstemi_suitable_for_invasive_strategy
    ESKD patients are systematically under-revascularised yet derive benefit; do not withhold on ESKD alone (2023 ESC ACS); ISCHEMIA-CKD informs STABLE disease, not ACS

outpatient playbook — drug actions (3)

  1. 1. antiplatelet maintenance (duration individualised)
    rxcui 1191
    aspirin 81 mg PO daily ± P2Y12 per bleeding-balanced duration • PO • daily
    trigger: Post-NSTEMI secondary prevention
    2023 ESC ACS — individualise in high-bleeding ESKD
  2. 2. high-intensity statin maintained
    rxcui 83367
    atorvastatin 40-80 mg PO daily • PO • daily
    trigger: Established ASCVD post-ACS
    Secondary prevention
  3. 3. RAAS/beta-blocker per LV function + tolerability
    rxcui 6918
    metoprolol + ACEi/ARB if LVSD and tolerated peri-dialysis • PO • daily
    trigger: Post-MI LV dysfunction
    GDMT adapted to dialysis haemodynamics

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Chest pain or anginal equivalent (dyspnoea, fatigue, intradialytic hypotension) in a maintenance-dialysis / advanced-CKD patient — NSTEMI with troponin-interpretation challenge; Troponin above the 99th-percentile URL in an ESKD patient — must establish whether this is a chronic stable baseline or an acute rise/fall; Significant serial troponin change (rise and/or fall, e.g. ≥20% from an elevated baseline or beyond assay biological variation) in a dialysis patient with ischaemic context — acute MI signature.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**NSTEMI in dialysis/ESKD — troponin delta (not absolute) drives diagnosis; renally-reconciled therapy** (cardio.nstemi.dialysis-troponin-interpretation.v1).
Scope: NSTEMI in ESKD: troponin is chronically elevated at baseline (especially hs-cTnT); diagnosis depends on a DYNAMIC rise/fall plus ischaemic context (4th UDMI), not a single absolute value. Cardiovascular death is the leading mortality cause; dialysis patients are systematically under-revascularised

No severity triggers fired against current inputs.

Plan

Regimen axis: **ESKD NSTEMI antithrombotic + anti-ischaemic therapy — UFH preferred for ACS anticoagulation in dialysis; renally reconcile all agents; do not withhold an invasive strategy on ESKD alone (4th UDMI; 2023 ESC ACS; ISCHEMIA-CKD)**.
1. aspirin 162-325 mg load then 81 mg PO daily PO daily (antiplatelet_cox1, first line) — 2023 ESC ACS — foundational antiplatelet; benefit maintained in CKD/ESKD though under-prescribed
2. ticagrelor 180 mg load then 90 mg PO BID PO BID (p2y12_inhibitor, first line) — 2023 ESC ACS — not renally dose-adjusted; PLATO renal subgroup showed preserved benefit; balance against high ESKD bleeding risk
3. clopidogrel 300-600 mg load then 75 mg PO daily PO daily (p2y12_inhibitor, second line) — No renal dose change; acceptable alternative when ticagrelor unsuitable; lower bleeding signal in very-high-risk ESKD
4. heparin (unfractionated) weight-based IV per ACS protocol, aPTT/anti-Xa titrated IV continuous, monitored (unfractionated_heparin, first line) — 2023 ESC ACS — UFH preferred in dialysis: titratable, not renally cleared, predictable peri-procedural management around dialysis
5. enoxaparin (renally reduced) 1 mg/kg SC ONCE daily (renal reduction) with anti-Xa monitoring if used SC daily (lmwh, second line) — Renally cleared — accumulates in ESKD; if used at all, reduce to once-daily with anti-Xa monitoring; UFH generally preferred
6. atorvastatin 80 mg PO daily (high-intensity) PO daily (statin, first line) — High-intensity statin for ACS; note dialysis-initiation statin trials (4D/AURORA) were neutral for primary prevention but ACS secondary prevention still indicated
7. metoprolol 12.5-25 mg PO BID, cautious uptitration PO BID (beta_blocker, add on) — Post-MI benefit; cautious dosing given intradialytic-hypotension and dialysability considerations (metoprolol partially dialysed)
8. AVOID fondaparinux in severe renal failure AVOID if CrCl <20-30 / dialysis N/A N/A (do_not_use, contraindication substitute) — 2023 ESC ACS / label — fondaparinux is renally cleared and contraindicated in severe renal impairment/dialysis (accumulation, bleeding)
9. AVOID reflexive enoxaparin treatment-dose without renal reduction AVOID standard BID treatment dosing in ESKD N/A N/A (do_not_use, contraindication substitute) — Accumulation → major bleeding; if LMWH used, reduce dose + anti-Xa monitor; UFH preferred
10. Coronary angiography ± PCI with radial access + dialysis timing Timely invasive strategy for confirmed type 1 NSTEMI; radial access; coordinate dialysis pre/post; protect residual renal function if not anuric N/A per risk stratification (invasive_strategy, rescue) — ESKD patients are systematically under-revascularised yet derive benefit; do not withhold on ESKD alone (2023 ESC ACS); ISCHEMIA-CKD informs STABLE disease, not ACS

Setting playbook (outpatient) — Long-term secondary prevention integrated with dialysis care; maintain a documented troponin baseline + assay for future delta interpretation; transplant cardiac clearance if a candidate
11. antiplatelet maintenance (duration individualised) aspirin 81 mg PO daily ± P2Y12 per bleeding-balanced duration PO daily — Post-NSTEMI secondary prevention (2023 ESC ACS — individualise in high-bleeding ESKD)
12. high-intensity statin maintained atorvastatin 40-80 mg PO daily PO daily — Established ASCVD post-ACS (Secondary prevention)
13. RAAS/beta-blocker per LV function + tolerability metoprolol + ACEi/ARB if LVSD and tolerated peri-dialysis PO daily — Post-MI LV dysfunction (GDMT adapted to dialysis haemodynamics)

Non-pharmacologic actions:
- Keep an updated baseline troponin + assay in the record
- Dialysis-prescription optimisation for volume/BP/anaemia
- Smoking cessation + CV risk modification
- Transplant cardiac clearance if candidate

AVOID / contraindication checks:
- Fondaparinux_contraindicated_in_severe_renal_failure_or_dialysis
- Enoxaparin_renal_dose_reduction_and_anti_xa_monitoring_in_eskd_ufh_preferred
- Beta_blocker_cautious_dosing_intradialytic_hypotension_and_dialysability
- Reconcile_doac_and_lmwh_doses_to_renal_function_even_if_anuric
- Protect_residual_renal_function_with_contrast_if_not_yet_anuric
- Decision:diagnosis_requires_dynamic_troponin_delta_not_absolute_value (4th UDMI)
- Decision:document_assay_used_hs_cTnT_more_elevated_than_hs_cTnI_in_eskd
- Decision:obtain_or_record_a_baseline_troponin_for_delta_interpretation
- Decision:do_not_down_triage_on_eskd_alone_grace_heart_amplified_by_eskd
- Decision:adjudicate_type1_vs_type2_vs_nonischaemic_before_anticoagulating_or_catheterising
- Decision:timely_invasive_strategy_for_type1_nstemi_radial_access_dialysis_timed
- Decision:type2_mi_treat_demand_driver_intradialytic_hypotension_anaemia_high_output_fistula
- Decision:establish_new_post_event_baseline_troponin_for_future_visits

Monitoring

Regimen monitoring:
- serial troponin trajectory against baseline to confirm rise fall
- document assay used and individualised delta threshold
- telemetry with attention to peri dialytic electrolyte shifts
- bleeding surveillance on dapt plus anticoagulant in high risk uraemia
- peri dialytic ischaemia and blood pressure surveillance
- post pci access site and av fistula graft checks
- electrolyte and volume management coordinated with nephrology

Setting (outpatient) monitoring:
- Periodic baseline troponin documentation
- DAPT/bleeding review
- Volume/BP/anaemia via dialysis unit
- Symptom surveillance for atypical ischaemia

Follow-up plan: Establish/record a new post-event baseline troponin for future interpretation; secondary prevention (statin, antiplatelet duration balanced against high bleeding risk, BP/volume control via dialysis prescription, anaemia management); cardiology–nephrology shared care; transplant-evaluation cardiac clearance if a candidate; document the assay used and the individualised delta threshold
- Close-out criterion: new baseline troponin + secondary prevention + shared-care plan documented

Monitoring phase: Serial troponin trajectory (confirm the rise/fall), telemetry (arrhythmia risk amplified by electrolyte shifts), peri-dialytic ischaemia surveillance, bleeding surveillance on antithrombotics, renal/electrolyte management with nephrology, post-PCI access + fistula checks

Disposition

Current setting: outpatient — Long-term secondary prevention integrated with dialysis care; maintain a documented troponin baseline + assay for future delta interpretation; transplant cardiac clearance if a candidate

Disposition criteria:
- Indefinite cardio-renal shared care; baseline troponin + assay maintained for lifelong delta-based interpretation

Escalation triggers (move to higher acuity):
- New significant troponin delta with symptoms → ED via ACS pathway
- Bleeding → de-escalate antithrombotics
- Progressive LV dysfunction → HF pathway

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] A clear rise and/or fall of troponin (e.g. ≥20% from an elevated baseline, or beyond assay biological variation) with ischaemic symptoms/ECG/imaging in an ESKD patient — type 1 NSTEMI, NOT "chronic ESKD elevation"
- [SEVERE] Major bleeding in an ESKD NSTEMI patient given fondaparinux or unreduced treatment-dose enoxaparin, or excessive DAPT, without renal reconciliation
- [MODERATE] A stable, chronically elevated troponin (no significant serial change) in an ESKD patient being treated as acute MI — risks unnecessary anticoagulation/catheterisation and bleeding harm

Citations

- 4th Universal Definition of MI (2018) + 2023 ESC ACS Guideline + 2025 ACC/AHA ACS framework + ISCHEMIA-CKD + KDIGO/KDOQI CV-in-CKD [PMID:30153967](https://pubmed.ncbi.nlm.nih.gov/30153967/)
- Cited evidence (PMID 37622654) [PMID:37622654](https://pubmed.ncbi.nlm.nih.gov/37622654/)
- Cited evidence (PMID 32860058) [PMID:32860058](https://pubmed.ncbi.nlm.nih.gov/32860058/)
- Cited evidence (PMID 32227755) [PMID:32227755](https://pubmed.ncbi.nlm.nih.gov/32227755/)
- Cited evidence (PMID 22922414) [PMID:22922414](https://pubmed.ncbi.nlm.nih.gov/22922414/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 4th Universal Definition of MI (2018) + 2023 ESC ACS Guideline + 2025 ACC/AHA ACS framework + ISCHEMIA-CKD + KDIGO/KDOQI CV-in-CKD — PMID:30153967
  • Cited evidence (PMID 37622654) — PMID:37622654
  • Cited evidence (PMID 32860058) — PMID:32860058
  • Cited evidence (PMID 32227755) — PMID:32227755
  • Cited evidence (PMID 22922414) — PMID:22922414